Evidence map›Paper›PMID 35245513›Full record

ArticleExperimental eye research2022

Long-term retinal protection by MEK inhibition in Pax6 haploinsufficiency mice.

James D Cole, Kara M McHaney, Behnam Rabiee, Jingyi Gao, Carlos Rodriguez, David A Miller, Mingna Liu, Marta Grannonico, Pedro Norat, Hao F Zhang and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental eye research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

James D ColeDepartment of Biology, University of Virginia, Charlottesville, VA, USA; Neuroscience Graduate Program, University of Virginia, Charlottesville, VA, USA.
Kara M McHaneyDepartment of Biology, University of Virginia, Charlottesville, VA, USA.
Behnam RabieeDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA; Department of Ophthalmology, Nazareth Hospital, Philadelphia, PA, USA.
Jingyi GaoDepartment of Biology, University of Virginia, Charlottesville, VA, USA.
Carlos RodriguezDepartment of Biology, University of Virginia, Charlottesville, VA, USA.
David A MillerDepartment of Biomedical Engineering, Northwestern University, Evanston, IL, USA.
Mingna LiuDepartment of Biology, University of Virginia, Charlottesville, VA, USA.
Marta GrannonicoDepartment of Biology, University of Virginia, Charlottesville, VA, USA.
Pedro NoratDepartment of Biology, University of Virginia, Charlottesville, VA, USA.
Hao F ZhangDepartment of Biomedical Engineering, Northwestern University, Evanston, IL, USA.
Ali R DjalilianDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: adjalili@uic.edu.
Xiaorong LiuDepartment of Biology, University of Virginia, Charlottesville, VA, USA; Department of Psychology, University of Virginia, Charlottesville, VA, USA; Program in Fundamental Neuroscience, University of Virginia, Charlottesville, VA, USA. Electronic address: xl8n@virginia.edu.
University of Virginia · USNorthwestern University · USUniversity of Illinois Chicago · US

Funding

Visual Signal Transformation in the Retinocollicular PathwayR01EY026286 · NEI · UNIVERSITY OF VIRGINIA · PI Jianhua Cang · 2016 to 2026
$4.4M
Novel Therapies for Ocular Chemical InjuriesR01EY024349 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DJALILIAN, ALI R · 2015 to 2020
$2.1M
Investigating nanoscale neuronal damages in early glaucoma towards clinical optical detectionR01EY029121 · NEI · NORTHWESTERN UNIVERSITY · PI LIU, XIAORONG, ZHANG, HAO F · 2018 to 2021
$2.0M
NEI NIH HHS R01 EY024349NEI NIH HHS R01 EY026286NEI NIH HHS R01 EY029121
6 · The paper itself

Abstract

Aniridia is a panocular condition characterized by impaired eye development and vision, which is mainly due to the haploinsufficiency of the paired-box-6 (PAX6) gene. Like what is seen in aniridia patients, Pax6-deficient mice Pax6

Indexed as

AniridiaPaired Box Transcription FactorsAnimalsDisease Models, AnimalEye ProteinsHaploinsufficiencyHomeodomain ProteinsHumansMiceMitogen-Activated Protein Kinase KinasesPAX6 Transcription FactorRepressor ProteinsRetinaEye ProteinsHomeodomain ProteinsMitogen-Activated Protein Kinase KinasesPaired Box Transcription FactorsPAX6 protein, humanPax6 protein, mousePAX6 Transcription FactorRepressor ProteinsAniridiaLong-term neuroprotectionMEK inhibitorPax6PD0325901Retinal damage

Identifiers

PMID35245513
PMCPMC9050935
OpenAlexW4214731851

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.